Safety and Efficacy of Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma Supplied by Extrahepatic Collateral Arteries

Lokken, R. Peter; Fidelman, Nicholas; Kolli, K.; Kerlan, Robert K.

doi:10.1016/j.jvir.2016.04.034

Cited by 10 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 a). Embolization of parasitized extrahepatic vessels was consistent with other reports in the literature [8 , 9] . No tumoral supply was observed from the right renal and lumbar arteries.…”

Section: Case Reportsupporting

confidence: 92%

Extrahepatic transarterial radioembolization to treat fibrolamellar hepatocellular carcinoma: A case report

Ljuboja

Weinstein

Ahmed

et al. 2020

Radiology Case Reports

View full text Add to dashboard Cite

Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare primary liver tumor that typically presents at an advanced stage in early adolescents and adults with no underlying liver disease. Surgical resection is the first-line treatment, and patients who are not surgical candidates face limited treatment options with poor long-term outcomes. Herein we report the first documented, technically successful treatment of FL-HCC with extrahepatic spread using transarterial radioembolization (TARE) in a 16-year-old male patient with surgically unresectable disease. Subsequent imaging revealed tumor necrosis and a 20% reduction in size, and the patient survived 20 months post-treatment, a marked improvement relative to historical data in the literature. Further research should examine the potential role of yttrium-90 TARE in the treatment of FL-HCC patients with metastatic disease.

show abstract

Section: Case Reportsupporting

confidence: 92%

Extrahepatic transarterial radioembolization to treat fibrolamellar hepatocellular carcinoma: A case report

Ljuboja

Weinstein

Ahmed

et al. 2020

Radiology Case Reports

View full text Add to dashboard Cite

show abstract

“…There have been concerns about skin toxicity in using TACE with drug-eluting beads for tumors with extrahepatic supply due to the risk of deposition of permanent embolic particles within terminal arteries supplying the skin, whereas the experience with conventional TACE is extensive in this setting. [37][38][39] TACE may be repeated multiple times provided that liver function remains adequate and as long as tumor-feeding arteries can be identified and catheterized. 40 Repeated radiation segmentectomy targeting multiple different liver segments may be risky due to the expected irreversible radiation injury to the targeted liver segments and the risk of cumulative hepatotoxicity.…”

Section: Local Regional Therapy For Tumor Downstagingmentioning

confidence: 99%

The Key Role of Staging Definitions for Assessment of Downstaging for Hepatocellular Carcinoma

2021

Self Cite

View full text Add to dashboard Cite

The success of liver transplant (LT) for hepatocellular carcinoma (HCC) is dependent on accurate tumor staging using validated imaging criteria, and adherence to acceptable criteria based on tumor size and number. Other factors including α-fetoprotein (AFP) and response to local regional therapy (LRT) have now played a larger role in candidate selection. Tumor downstaging is defined as reduction in the size of viable tumors using LRT to meet acceptable criteria for LT, and serves as a selection tool for a subgroup of HCC with more favorable biology. The application of tumor downstaging requires a structured approach involving three key components in tumor staging—initial tumor stage and eligibility criteria, tumor viability assessment following LRT, and target tumor stage prior to LT—and incorporation of AFP into staging and treatment response assessments. In this review, we provide in-depth discussions of the key role of these staging definitions in ensuring successful outcome.

show abstract

“…Arterioembolic therapies can precipitate or exacerbate liver failure from ischemic damage, even when embolization is performed via extrahepatic collateral arteries. 108 The risk of liver failure increases with advanced cirrhosis. 109 Patients with serum bilirubin level 4.0 mg/dL, the elevated international normalized ratio for prothrombin time, hypoalbuminemia, moderate or large Fig.…”

Section: Hepatic Failurementioning

confidence: 99%

Toxicity of Liver-Directed Therapies for Hepatocellular Carcinoma

Lee

Fidelman

2017

Dig Dis Interv

Self Cite

View full text Add to dashboard Cite

The purpose of this review is to outline the various toxicities of liver-directed therapy approaches employed for treatment of liver-limited hepatocellular carcinoma. The covered topics span toxicities related to ablative and transarterial treatment approaches, including radiofrequency and microwave ablation, cryoablation, percutaneous ethanol injection, transarterial chemoembolization, and yttrium-90 radioembolization. Both common entities, such as postablation, and post(radio)embolization syndrome and hepatotoxicity, as well as uncommon topics (nontarget organ damage, cryoshock, infections, bile duct injuries) are described. Appropriate treatments for management of these side effects are suggested.

show abstract

Safety and Efficacy of Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma Supplied by Extrahepatic Collateral Arteries

Cited by 10 publications

References 29 publications

Extrahepatic transarterial radioembolization to treat fibrolamellar hepatocellular carcinoma: A case report

Extrahepatic transarterial radioembolization to treat fibrolamellar hepatocellular carcinoma: A case report

The Key Role of Staging Definitions for Assessment of Downstaging for Hepatocellular Carcinoma

Toxicity of Liver-Directed Therapies for Hepatocellular Carcinoma

Contact Info

Product

Resources

About